Ask AI
Search
Updates
Library
Diseases
Studies
Pathways
Calculators
Findings
Drugs
Preview
Specialties
Home
New Question
Answer
Psilocybin and methylenedioxymethamphetamine (MDMA) have shown promise in the treatment of depression and post-traumatic stress disorder (PTSD), respectively, in recent clinical research.
1.
Psilocybin in MDD
2.
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
4.
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
5.
3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
3.
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
In conclusion, both psilocybin and MDMA have shown promise in the treatment of depression and PTSD, respectively. However, further research is needed to fully understand their potential and safety profiles in these contexts.
References
1
JAMA 2023
2
BMJ 2024
Show all references